Non insulin-dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.
Indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:
-Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).
or
-Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI
Registration
Biological Drug
FluMist
Influenza vaccine (intranasal, live attenuated) (LAIV trivalent): Influenza Virus Type A H1N1, Influenza Virus Type A H3N2, Influenza Virus Type B (Victoria lineage)
Influenza vaccine (intranasal, live attenuated) (LAIV trivalent): Influenza Virus Type A H1N1, Influenza Virus Type A H3N2, Influenza Virus Type B (Victoria lineage)
الاستخدامات الطبية المعتمدة
FluMist is indicated for the prophylaxis of influenza in individuals from 2 to less than 18 years of age.
Registration
Biological Drug
FluMist
Influenza vaccine (intranasal, live attenuated) (LAIV trivalent): Influenza Virus Type A H1N1, Influenza Virus Type A H3N2, Influenza Virus Type B (Victoria lineage) 107±0.5 FFU Influenza Virus Type B (Victoria lineage)
Influenza vaccine (intranasal, live attenuated) (LAIV trivalent): Influenza Virus Type A H1N1, Influenza Virus Type A H3N2, Influenza Virus Type B (Victoria lineage) 107±0.5 FFU Influenza Virus Type B (Victoria lineage)
الاستخدامات الطبية المعتمدة
FluMist is indicated for the prophylaxis of influenza in individuals from 2 to less than 18 years of age.
Lijen Met is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:
• In patients inadequately controlled on their maximally tolerated dose of metformin alone.
• In combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products.
In patients already being treated with the combination of linagliptin and metformin as separate tablets.
Lijen Met is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:
• In patients inadequately controlled on their maximally tolerated dose of metformin alone.
• In combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products.
In patients already being treated with the combination of linagliptin and metformin as separate tablets.
